FI20041489L - Menetelmä atorvastatiini kalsiumin valmistamiseksi amorfisessa muodossa - Google Patents

Menetelmä atorvastatiini kalsiumin valmistamiseksi amorfisessa muodossa Download PDF

Info

Publication number: FI20041489L
Authority: FI; Finland
Prior art keywords: amorphous form; atorvastatin calcium; preparing atorvastatin; preparing; calcium
Prior art date: 2004-03-17

Application number

FI20041489A

Other languages

English (en)

Swedish (sv)

Other versions

FI120344B (fi

FI20041489A0 (fi

Inventor

Yatendra Kumar

Saridi Madhava Dileep Kumar

Swargam Sathyanarayana

Original Assignee

Ranbaxy Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-17

Filing date

2004-11-19

Publication date

2006-07-20

2004-11-19 Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd

2004-11-19 Publication of FI20041489A0 publication Critical patent/FI20041489A0/fi

2005-09-16 Priority to EP05077109A priority Critical patent/EP1659110A1/en

2006-07-20 Publication of FI20041489L publication Critical patent/FI20041489L/fi

2009-09-30 Application granted granted Critical

2009-09-30 Publication of FI120344B publication Critical patent/FI120344B/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Obesity (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI20041489A 2004-03-17 2004-11-19 Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi FI120344B (fi)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP05077109A EP1659110A1 (en)	2004-03-17	2005-09-16	Process for the production of atorvastatin calcium un amorphous form

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN491DE2004		2004-03-17
IN491DE2004		2004-03-17

Publications (3)

Publication Number	Publication Date
FI20041489A0 FI20041489A0 (fi)	2004-11-19
FI20041489L true FI20041489L (fi)	2006-07-20
FI120344B FI120344B (fi)	2009-09-30

Family

ID=33516010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI20041489A FI120344B (fi)	2004-03-17	2004-11-19	Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi

Country Status (17)

Country	Link
US (1)	US7994343B2 (fi)
EP (3)	EP1727795B1 (fi)
CN (2)	CN1942439B (fi)
AR (1)	AR048271A1 (fi)
AT (1)	ATE545629T1 (fi)
AU (2)	AU2004317570B2 (fi)
CA (3)	CA2666359A1 (fi)
CY (1)	CY1112583T1 (fi)
DK (1)	DK1727795T3 (fi)
ES (1)	ES2381473T3 (fi)
FI (1)	FI120344B (fi)
MY (1)	MY147435A (fi)
NO (1)	NO330092B1 (fi)
PL (1)	PL1727795T3 (fi)
PT (1)	PT1727795E (fi)
SI (1)	SI1727795T1 (fi)
WO (1)	WO2005092852A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1727795T3 (pl) *	2004-03-17	2012-06-29	Ranbaxy Laboratories Ltd	Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
CA2833770A1 (en) *	2004-07-16	2006-01-26	Lek Pharmaceuticals D.D	Oxidative degradation products of atorvastatin calcium
US7645888B2 (en) *	2004-08-27	2010-01-12	Biocon Limited	Process for the production of amorphous atorvastatin calcium
GB2424880A (en) *	2005-04-06	2006-10-11	Generics	Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
CN101268047B (zh)	2005-08-15	2012-11-07	箭锋国际有限公司	结晶和无定形阿托伐他汀钠
GB0613567D0 (en) *	2006-07-07	2006-08-16	Arrow Int Ltd	Crystalline sodium atorvastatin
GB0613566D0 (en) *	2006-07-07	2006-08-16	Arrow Int Ltd	Crystalline sodium atorvastatin
BRPI0614279A2 (pt)	2005-08-15	2012-11-06	Arrow Int Ltd	atorvastatina sódica cristalina e amorfa
ES2270722B1 (es) *	2005-09-15	2008-03-01	Ercros Industrial, S.A.	Procedimiento para la obtencion de atorvastatina calcica amorfa.
GB0523637D0 (en) *	2005-11-21	2005-12-28	Avecia Pharmaceuticals Ltd	Process and compounds
WO2007099552A2 (en) *	2006-03-02	2007-09-07	Matrix Labaratories Ltd	Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) *	2006-04-14	2007-10-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
CN101205209B (zh) *	2007-12-25	2010-06-02	浙江新东港药业股份有限公司	一种阿伐他汀中间体的精制方法
EP2075246A1 (en) *	2007-12-27	2009-07-01	M. J. Institute of Research	A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101468963B (zh) *	2007-12-28	2012-09-19	石药集团中奇制药技术（石家庄）有限公司	一种无定形阿伐他汀钙的制备方法
KR100850558B1 (ko) *	2008-01-02	2008-08-06	조동옥	아토르바스타틴의 효율적인 제조방법
CN101560177B (zh) *	2008-04-16	2012-10-03	北京万全阳光医学技术有限公司	一种阿托伐他汀钙的制备方法
CN101429195B (zh) *	2008-11-03	2010-12-15	华东师范大学	一种高纯度阿托伐他汀重要合成中间体的制备方法
US8115015B2 (en)	2009-01-26	2012-02-14	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
SI2560951T1 (sl) *	2010-04-19	2016-10-28	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Proizvodnja atorvastanina z nizko vsebnostjo etrskih nečistoč
CN102127060B (zh) *	2010-12-17	2013-12-04	蚌埠丰原医药科技发展有限公司	一种阿托伐他汀钙中间体的制备方法
CN102070504A (zh) *	2010-12-23	2011-05-25	蚌埠丰原医药科技发展有限公司	阿托伐他汀钠的制备方法
CN102070505B (zh) *	2011-01-28	2012-01-11	海南美大制药有限公司	阿托伐他汀钙化合物及其新制法
CN103483238B (zh) *	2013-08-20	2014-12-31	蚌埠丰原医药科技发展有限公司	阿托伐他汀钙三水合物的制备方法
CN104945300B (zh) *	2015-06-17	2017-05-10	北京嘉林药业股份有限公司	一种ⅰ型阿托伐他汀钙的纯化方法
WO2017060885A1 (en) *	2015-10-09	2017-04-13	Laurus Labs Private Limited	An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
CN106478591B (zh) *	2016-09-30	2018-11-13	北京嘉林药业股份有限公司	一种阿托伐他汀缩合物中间体的拆分方法
CN106432033B (zh) *	2016-10-21	2018-07-27	江苏阿尔法药业有限公司	一种无定形阿托伐他汀钙的制备方法
CN108033899B (zh) *	2017-12-06	2020-04-10	浙江科技学院	一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法
CN109280024A (zh) *	2018-10-09	2019-01-29	河南师范大学	一种高纯度阿托伐他汀叔丁酯的制备方法
CN109232355A (zh) *	2018-10-09	2019-01-18	河南师范大学	一种有效去除阿托伐他汀钙粗品中杂质阿托伐他汀缩合物的方法
CN110563628B (zh) *	2019-08-26	2022-04-05	北京嘉林药业股份有限公司	一种双釜制备高纯度和单分散i晶型阿托伐他汀钙的结晶方法
CN110776451B (zh) *	2020-01-02	2020-05-22	湖南迪诺制药股份有限公司	一种i晶型阿托伐他汀钙的制备方法
CN113695307B (zh) *	2020-05-20	2022-12-02	天津嘉林科医有限公司	一种盛放阿托伐他汀钙的玻璃器皿的清洗方法
WO2025147589A1 (en)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5216174A (en)	1988-02-22	1993-06-01	Warner-Lambert Co.	Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en)	1988-02-22	1992-09-22	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en)	1989-02-01	1992-03-17	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en)	1988-02-22	1992-06-23	Warner-Lambert Company	Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en)	1988-02-22	1993-09-14	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en)	1990-10-17	1992-04-07	Warner-Lambert Company	Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en)	1990-10-17	1993-09-28	Warner-Lambert Company	Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en)	1991-10-11	1992-10-13	Warner-Lambert Company	Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
DE69324504T2 (de)	1993-01-19	1999-08-26	Warner-Lambert Co.	Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HU223599B1 (hu)	1995-07-17	2004-10-28	Warner-Lambert Company	I,II és IV kristályformájú [R-(R,R)]-2(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-[(fenil-amino)-karbonil]-1H-pirrol-1-heptánkarbonsav-hemikalciumsó-hidrát (atorvasztatin-hidrát) és a vegyületeket tartalmazó gyógyászati készítmények
HRP960312B1 (en)	1995-07-17	2001-10-31	Warner Lambert Co	NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R, R)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (fi)	1999-05-25	2003-10-11	Ranbaxy Lab Ltd
HU226640B1 (en)	1999-10-18	2009-05-28	Egis Gyogyszergyar Nyilvanosan	Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) *	2000-10-17	2003-11-11	Egis Gyogyszergyar Rt.	Process for the preparation of amorphous atorvastatin calcium
SI20425A (sl) *	1999-12-10	2001-06-30	LEK tovarna farmacevtskih in kemi�nih izdelkov d.d.	Priprava amorfnega atorvastatina
HRP20020950A2 (en)	2000-06-09	2004-12-31	Lek Tovarna Farmacevtskih	Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
PL362472A1 (en)	2000-11-03	2004-11-02	Teva Pharma	Atorvastatin hemi-calcium form vii
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057225A2 (en)	2000-12-18	2002-07-25	Merck & Co., Inc.	Thrombin inhibitors
SK9532003A3 (en)	2000-12-27	2004-04-06	Ciba Sc Holding Ag	Crystalline forms of atorvastatin calcium
WO2002057228A1 (en)	2001-01-17	2002-07-25	Biocon India Limited	Atorvastatin calcium
SI20814A (sl)	2001-01-23	2002-08-31	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Priprava amorfnega atorvastatina
IN190564B (fi)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
JP3965155B2 (ja)	2001-06-29	2007-08-29	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	結晶型［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）（アトロバスタチン）
JP2005500351A (ja)	2001-07-30	2005-01-06	ドクター・レディーズ・ラボラトリーズ・リミテッド	結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
AU2001284385A1 (en)	2001-08-31	2003-03-10	Morepen Laboratories Ltd.	An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CZ296967B6 (cs) *	2002-02-01	2006-08-16	Zentiva, A.S.	Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
HUP0500074A3 (en)	2002-03-18	2005-07-28	Biocon Ltd Bangalore	Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
WO2003099785A1 (en)	2002-05-28	2003-12-04	Cadila Healthcare Limited	Process for the preparation of amorphous atorvastatin calcium
SI21302A (sl)	2002-10-11	2004-04-30	LEK farmacevtska dru�ba d.d.	Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HU227041B1 (en)	2003-03-24	2010-05-28	Richter Gedeon Nyrt	Process for the synthesis of amorphous atorvastatin calcium
PL1727795T3 (pl) *	2004-03-17	2012-06-29	Ranbaxy Laboratories Ltd	Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
CN101124230A (zh)	2004-09-28	2008-02-13	特瓦制药工业有限公司	制备基本无杂质的阿托伐他汀钙形式的方法

2004
- 2004-11-19 PL PL04798913T patent/PL1727795T3/pl unknown
- 2004-11-19 AU AU2004317570A patent/AU2004317570B2/en not_active Ceased
- 2004-11-19 CA CA002666359A patent/CA2666359A1/en not_active Abandoned
- 2004-11-19 FI FI20041489A patent/FI120344B/fi not_active IP Right Cessation
- 2004-11-19 CA CA002627940A patent/CA2627940A1/en not_active Abandoned
- 2004-11-19 US US10/549,890 patent/US7994343B2/en not_active Expired - Fee Related
- 2004-11-19 PT PT04798913T patent/PT1727795E/pt unknown
- 2004-11-19 CA CA002560252A patent/CA2560252C/en not_active Expired - Fee Related
- 2004-11-19 WO PCT/IB2004/003789 patent/WO2005092852A1/en not_active Ceased
- 2004-11-19 ES ES04798913T patent/ES2381473T3/es not_active Expired - Lifetime
- 2004-11-19 SI SI200431843T patent/SI1727795T1/sl unknown
- 2004-11-19 CN CN2004800428343A patent/CN1942439B/zh not_active Expired - Fee Related
- 2004-11-19 AT AT04798913T patent/ATE545629T1/de active
- 2004-11-19 EP EP04798913A patent/EP1727795B1/en not_active Expired - Lifetime
- 2004-11-19 EP EP04027584A patent/EP1577297A1/en not_active Withdrawn
- 2004-11-19 DK DK04798913.2T patent/DK1727795T3/da active
- 2004-11-19 NO NO20045037A patent/NO330092B1/no not_active IP Right Cessation
2005
- 2005-03-16 AR ARP050101018A patent/AR048271A1/es unknown
- 2005-03-17 CN CNA200580012704XA patent/CN1946688A/zh active Pending
- 2005-03-17 MY MYPI20051161A patent/MY147435A/en unknown
- 2005-09-16 EP EP05077109A patent/EP1659110A1/en not_active Ceased
2010
- 2010-12-03 AU AU2010249166A patent/AU2010249166B2/en not_active Ceased
2012
- 2012-04-04 CY CY20121100335T patent/CY1112583T1/el unknown

Also Published As

Publication number	Publication date
AR048271A1 (es)	2006-04-12
CN1942439B (zh)	2011-12-21
AU2004317570A1 (en)	2005-10-06
EP1577297A1 (en)	2005-09-21
US7994343B2 (en)	2011-08-09
CA2666359A1 (en)	2005-10-06
ATE545629T1 (de)	2012-03-15
NO330092B1 (no)	2011-02-14
AU2004317570B2 (en)	2011-01-06
CA2560252C (en)	2009-08-04
EP1659110A1 (en)	2006-05-24
SI1727795T1 (sl)	2012-05-31
NO20045037D0 (no)	2004-11-19
CN1946688A (zh)	2007-04-11
AU2010249166A1 (en)	2010-12-23
FI120344B (fi)	2009-09-30
ES2381473T3 (es)	2012-05-28
EP1727795B1 (en)	2012-02-15
DK1727795T3 (da)	2012-04-16
PL1727795T3 (pl)	2012-06-29
FI20041489A0 (fi)	2004-11-19
CA2560252A1 (en)	2005-10-06
CN1942439A (zh)	2007-04-04
EP1727795A1 (en)	2006-12-06
US20100197941A1 (en)	2010-08-05
CA2627940A1 (en)	2005-10-06
CY1112583T1 (el)	2016-02-10
PT1727795E (pt)	2012-04-11
AU2010249166B2 (en)	2012-02-09
WO2005092852A1 (en)	2005-10-06
NO20045037L (no)	2005-09-19
MY147435A (en)	2012-12-14

Publication	Publication Date	Title
FI20041489L (fi)	2006-07-20	Menetelmä atorvastatiini kalsiumin valmistamiseksi amorfisessa muodossa
FI20040775L (fi)	2005-12-05	Menetelmä etanolin valmistamiseksi
PL2351578T3 (pl)	2017-07-31	Sposób wytwarzania szczepionek
IL182474A0 (en)	2007-07-24	Process for forming amorphous atorvastatin
PL1960321T3 (pl)	2014-10-31	Sposób wytwarzania elementów i konstrukcji z betonu
EP1793815A4 (en)	2010-12-29	AMORPHES ATORVASTATINCALCIUM
TWI369218B (en)	2012-08-01	In situ forming implant for animals
PL1899297T3 (pl)	2016-06-30	Zofenopryl wapnia w postaci polimorficznej c
FI20040290L (fi)	2005-08-26	Menetelmä kuitupohjaisen materiaalin saumaamiseksi
EP1804817A4 (en)	2009-11-11	METHODS OF PROMOTING WOUND HEALING
ZA200608632B (en)	2008-06-25	Process for forming amorphous atorvastatin calcium
EP1809313A4 (en)	2008-01-23	PROCESS FOR PROMOTING WOUND HEALING
FI20065595L (fi)	2006-09-26	Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
FI20065594L (fi)	2006-09-26	Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
PL1858851T3 (pl)	2015-11-30	Sposób otrzymywania amorficznej lerkanidypiny
IL180870A0 (en)	2009-02-11	Method for preparing n-aminopiperedine and its salts
JP2005281246A5 (ja)	2007-09-20	シラザプリルの製造方法
EP1932822A4 (en)	2010-07-14	DEHYDRATION PROCESS
FI20055425A7 (fi)	2007-02-06	Menetelmä turpeen tuottamiseksi
ITBO20040397A1 (it)	2004-09-24	Bauletto per ciclo
UA9112S (uk)	2004-07-15	Форма для бетону
SE0402211D0 (sv)	2004-09-14	Method
ITCH20040003A1 (it)	2004-04-13	Metodo trainig cane-conduttore
SE0402212D0 (sv)	2004-09-14	Method
FR2877552B1 (fr)	2007-03-02	Rotule pour sommier de literie

Legal Events

Date	Code	Title	Description
2009-09-30	FG	Patent granted	Ref document number: 120344 Country of ref document: FI
2012-07-05	MM	Patent lapsed

Date

Code

Title

Description

2009-09-30

Patent granted

Ref document number: 120344

Country of ref document: FI

2012-07-05

Patent lapsed